PREVENTION OF POSTNATAL DEPRESSION IN CONDITIONS OF THE STROKE CENTER

Muratova T. M., Khramtsov D. M., Vorokhta Yu. M., Vikarenko M. S.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The purpose of the study was to evaluate the effectiveness of prevention of postnatal depression (PID) in patients with acute cerebrovascular accident. Object and methods. The study was performed at the stroke unit of the neurological department of the University Clinic of the Odessa National Medical University during 2016-2018. Under supervision, there were 217 patients with acute ischemic stroke. The examination and treatment were carried out in accordance with the requirements of the order N 602 d. 03.082012 “On approval and implementation of medical-technological documents on the standardization of medical care for ischemic stroke”. Additionally, the severity of depressive manifestations was evaluated using the HADS-D scale in patients with preserved speech function (n = 159). Clinical results with the use of various antidepressants were analysed. The term of follow-up observation was 6 months. Statistical processing was performed using the software Statistica 10.0 (Dell StatSoft Inc., USA). Results. Males (52.0%) prevailed in the study sample. The average age was 60.4±1.1 years, the average NIHSS score was 10.1±0.09. 149 (68.7%) patients were admitted to the clinic during the first day after the first clinical manifestations of stroke. The average length of stay in the hospital was 10.2±0.9 days. Manifestations of postnatal depression were identified in 53 (33.3%) patients whose average age was 54.2±1.5 years. 67.9% of patients received various SIRS in the standard doses and other patients received vortioxetine in a dosage of 10-20 mg per day. At the time of the initial survey, the score on the HADS-D scale was an average of 8.8±0.1 points. Six months after discharge, patients continued receiving drugs, those receiving SIRS average score on the HADS-D scale was 7.7±0.1 points, and in patients taking vortioxetin – 6.2±0.1 scores. Conclusion. It was shown that the incidence of post-stroke depression in patients with ischemic stroke exceeds 30%. In assessing the role of various risk factors among the examined patients with PID, the prevalence of male patients (OR = 1.3 (1.1-1.5)), under the age of 55 (1.7 (1.3-1.9)), with the history of depression episodes in the past (1.6 (1.4-1.8)), as well as alcohol abuse (1.2 (1.0-1.3)). In 31 (58.5%) cases focal ischemia was localised in the frontal lobe of the dominant hemisphere. The use of both SIRS and an antidepressant with multimodal effect – vortioxetine was sufficiently effective in postnatal depression whereas vortioxetin showing the best results. The paper considers the expediency of the use of vortioxetin for preventing PID in patients with ischemic stroke.

postnatal depression, ischemic stroke, diagnosis, treatment.

1. Espárrago Llorca G, Castilla-Guerra L, Fernández Moreno MC, Ruiz Doblado S, Jiménez Hernández MD. Post-stroke depression: an update. Neurologia. 2015 Jan-Feb;30(1):23-31.
2. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. Am J Psychiatry. 2016 Mar 1;173(3):221-31.
3. Schöttke H, Giabbiconi CM. Post-stroke depression and post-stroke anxiety: prevalence and predictors. Int Psychogeriatr. 2015 Nov;27(11): 1805-12.
4. Schulte-Altedorneburg M, Bereczki D. Post-stroke depression. Orv Hetil. 2014 Aug 24;155(34):1335-43.
5. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition: DSM-5 American Psychiatric Publishing; 5 edition. May 27, 2013. 991 р.
6. Villa RF, Ferrari F, Moretti A. Post-stroke depression: Mechanisms and pharmacological treatment. Pharmacol Ther. 2018 Apr;184:131-44.
7. Ilut S, Stan A, Blesneag A, Vacaras V, Vesa S, Fodoreanu L. Factors that influence the severity of post-stroke depression. J Med Life. 2017 JulSep;10(3):167-71.
8. Douven E, Köhler S, Rodriguez MMF, Staals J, Verhey FRJ, Aalten P. Imaging Markers of Post-Stroke Depression and Apathy: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2017 Sep;27(3):202-19.
9. Wei N, Yong W, Li X, Zhou Y, Deng M, Zhu H, et al. Post-stroke depression and lesion location: a systematic review. J Neurol. 2015 Jan;262(1): 81-90.
10. Levada OA, Troyan AS. Poststroke Depression Biomarkers: A Narrative Review. Front Neurol. 2018 Jul 16;9:577.
11. Nabavi SF, Turner A, Dean O, Sureda A, Mohammad S. Post-stroke depression therapy: where are we now? Curr Neurovasc Res. 2014;11(3): 279-89.
12. Chan CH, Huang HH, Lin CH, Kuan YC, Loh EW, Lan TH. Risk of First Onset Strokein SSRI-Exposed Adult Subjects: Survival Analysis and Examination of Age and Time Effects. J Clin Psychiatry. 2017 Sep/Oct;78(8):e1006-e1012.
13. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl). 2017 Oct;234(20):3075-81.
14. Dong YH, Bykov K, Choudhry NK, Donneyong MM, Huybrechts KF, Levin R, et al. Clinical Outcomes of Concomitant Use of Warfarin and Selective Serotonin Reuptake Inhibitors: A Multidatabase Observational Cohort Study. J Clin Psychopharmacol. 2017 Apr;37(2):200-9.
15. Russo NW, Petrucci G, Rocca B. Aspirin, stroke and drug-drug interactions. Vascul Pharmacol. 2016 Dec;87:14-22.
16. Nakaz MOZ Ukraуny vid 04.09.2014 № 620 «Pro zatverdzhennya ta vprovadzhennya medyko-tekhnolohichnykh dokumentiv zi standartyzatsiі medychnoі dopomohy pry tuberkulʹozi». Dostupno: http://old.moz.gov.ua/ua/portal/dn_20140904_0620.html [in Ukrainian].
17. Pietra Pedroso VS, Rachid MA, Teixeira AL. Biomarkers in Post-stroke Depression. Curr Neurovasc Res. 2016;13(2):163-73.
18. Bartoli F, Paolucci S. Association of depression and SSRIs with mortality after stroke. Neurology. 2014 Nov 25;83(22):1998-9.

«Bulletin of problems biology and medicine» Issue 3 (152), 2019 year, 156-160 pages, index UDK 10.21518/2079-701Х-2017-0-47-51

10.29254/2077-4214-2019-3-152-156-160